Comparison of ixekizumab with ustekinumab in patients with baseline PASI>15 and/or at-least 3previous-non-biologic-therapies-treatment-failures: 24-week post-hoc-analysis from a randomized trial (IXORA-S;NCT02561806)
Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled, phase 3b clinical trial in patients with moderate-to-severe genital psoriasis
Essential information for estimating total PASI: A model developed from phase 3 trials of ixekizumab (IXE) for application in teledermatology
Ixekizumab provides sustained improvement in signs and symptoms in patients with active psoriatic arthritis: Results from a phase 3 trial
Matching-adjusted indirect comparisons of ixekizumab and secukinumab using etanercept and ustekinumab bridge comparators
To give or not to give, that is still the question: A 10 year TEN experience at NSW referral centre
Blue vitiligo: A case report
“Idiopathic hyperkeratotic migratory flexural erythema” successfully treated with oral amoxicillinclavulanic acid: A report of 3 cases
Sustained improvement in patient-reported outcomes with continued apremilast treatment over 104 weeks in patients with moderate to severe psoriasis
A hedgehog opportunity: Management of multiple basal cell carcinomas in a patient treated for acne with facial radiation therapy
Treatment of Hailey-Hailey disease with botulinum toxin
Ultrasound in the diagnosis and staging of hidradenitis suppurativa
Acute non–sexually acquired genital ulceration in a post-partum woman
Air travel induced cutaneous leucocytoclastic vasculitis
How to become a dermatologist in the Netherlands!
The correlation of sebaceous hyperplasia and colonic polyposis: An observational study
Don’t point the finger: Laxative abuse induced nail clubbing
2023 Dermcoll, 55TH ANNUAL SCIENTIFIC MEETING, THE ART OF DERMATOLOGY
2022 Dermcoll, 54TH ANNUAL SCIENTIFIC MEETING, THE ART OF DERMATOLOGY